ArticleScientific reports2021
Blood biomarkers of progressive atherosclerosis and restenosis after stenting of symptomatic intracranial artery stenosis.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Neutrophil-to-lymphocyte ratio as a potential biomarker in predicting in-stent restenosis: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Identifying risk factors for in-stent restenosis in symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis.Frontiers in neurology · 2023Pooled it
- Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial.Cardiovascular diabetology · 2023 · on this mapTrial
- Predictive Value of Baseline High-Resolution MRI Features for In-Stent Restenosis in Symptomatic Nonacute Intracranial Atherosclerotic Occlusion.Cardiovascular and interventional radiology · 2026Article
- Seeing Intracranial in-Stent Restenosis Before it Happens: What Baseline Vessel Wall Imaging Can-and Can't-Tell Us Yet.Cardiovascular and interventional radiology · 2026Article
- The HCG11/QKI5 Axis Regulates Endothelial Angiogenic Adaptation During Chronic Cerebral Hypoperfusion.CNS neuroscience & therapeutics · 2026Article
- Inflammatory Biomarkers and Their Associations with Arrhythmic Burden Following SGLT2-I Treatment in Chronic Heart Failure-A Subanalysis of the ERASe Trial.Journal of clinical medicine · 2026Article
- Pre-procedural C-reactive protein levels and carotid or intracranial artery restenosis: A systematic review and meta-analysis.Atherosclerosis plus · 2026Article
- Prognostic Factors for In-stent Restenosis After Cerebrovascular Stent Implantation among Ischemic Stroke Patients.Current neurovascular research · 2026Article
- Protective Factors of Postendovascular Therapy Restenosis for Symptomatic Intracranial Arterial Stenosis: A Retrospective Analysis.AJNR. American journal of neuroradiology · 2025Article
- Carotid Plaque Characteristics Combined With Serum Inflammatory Biomarkers Predict Recurrent Ischemic Stroke.Brain and behavior · 2025Article
- Elevated high-sensitivity C-reactive protein levels are associated with intracranial arterial stenosis in elderly patients.BMC neurology · 2025Article
- Alterations in metabolome and lipidome in patients with in-stent restenosis.CNS neuroscience & therapeutics · 2024Article
- Hemodynamic and Geometric Risk Factors for In-Stent Restenosis in Patients with Intracranial Atherosclerotic Stenosis.Oxidative medicine and cellular longevity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In-stent restenosis (ISR) represents a major complication after stenting of intracranial artery stenosis (ICAS). Biomarkers derived from routine blood sampling including C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and mean platelet volume (MPV) have been associated with progressive atherosclerosis. We investigated the role of CRP, NLR, PLR and MPV on the development of intracranial ISR and recurrent stroke risk. We retrospectively included all patients who had undergone stenting of symptomatic ICAS at our university hospital between 2005 and 2016. ISR (≥ 50% stenosis) was diagnosed by regular Duplex sonography follow-up studies and confirmed by digital subtraction angiography or computed tomography angiography (mean follow-up duration: 5 years). Laboratory parameters were documented before stenting, at the time of restenosis and at last clinical follow-up. Of 115 patients (mean age: 73 ± 13 years; female: 34%), 38 (33%) developed ISR. The assessed laboratory parameters did not differ between patients with ISR and those without (p > 0.1). While ISR was associated with the occurrence of recurrent ischemic stroke (p = 0.003), CRP, NLR, PLR and MPV were not predictive of such events (p > 0.1). Investigated blood biomarkers of progressive atherosclerosis were not predictive for the occurrence of ISR or recurrent ischemic stroke after ICAS stenting during a 5-year follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.